title: Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.
abstract: In a prospective, randomized, assessor-blind multicentre study two antithrombotic subcutaneous regimens were compared in patients undergoing total hip replacement. Group 1 (154 patients) received 750 anti-Xa units of a new low molecular weight heparinoid (Lomoparan) subcutaneously twice a day and group 2 (155 patients) received 5000 units heparin and 0.5 mg dihydroergotamine (heparin-DHE 5000) twice a day. The incidence of deep vein thrombosis, assessed by routine bilateral venography on day 10 (+/- 1), was 17 and 32 per cent in groups 1 and 2 respectively (risk reduction 47 per cent; P = 0.007). One patient in each group developed a symptomatic pulmonary embolism confirmed by lung scanning. Major bleeding complications occurred in one patient in each group and no significant difference was observed between the two groups with respect to minor bleeding complications. Subcutaneous Lomoparan appears to be as safe as heparin-DHE 5000 at the above doses with regard to bleeding complications, and is more efficacious with respect to venous thrombosis.
authors.affiliation: Department of Orthopaedics, Hôpital Orthopédique, Lausanne, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Leyvraz
authors.forename: F
authors.initials: F
authors.lastname: Bachmann
authors.forename: J
authors.initials: J
authors.lastname: Bohnet
authors.forename: H G
authors.initials: HG
authors.lastname: Breyer
authors.forename: D
authors.initials: D
authors.lastname: Estoppey
authors.forename: S
authors.initials: S
authors.lastname: Haas
authors.forename: J
authors.initials: J
authors.lastname: Hochreiter
authors.forename: H
authors.initials: H
authors.lastname: Jakubek
authors.forename: J
authors.initials: J
authors.lastname: Mair
authors.forename: R
authors.initials: R
authors.lastname: Sorensen
mesh_terms: D000368:Aged; D016063:Blood Loss, Surgical; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004087:Dihydroergotamine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D011446:Prospective Studies; D013923:Thromboembolism / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000517:prevention & control*
chemical_list: D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004087:Dihydroergotamine; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; C031388:heparin-dihydergot; C035838:danaparoid